Novel biologics for treatment of chronic spontaneous urticaria.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 36180286.
- Also identified by DOI 10.1016/j.jaci.2022.06.027.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Chronic idiopathic/spontaneous urticaria (CIU/CSU) causes significant impairments in quality of life and is often unresponsive to antihistamines. Although the anti-IgE mAb omalizumab has been an important addition to the therapeutic armamentarium for the management of patients with CSU, there are still a significant percentage of patients who do not respond to the combination of antihistamines and omalizumab. As a result, additional treatments are needed. With the expanding knowledge of the pathogenesis of CSU and the role of mast cells, novel therapeutic agents targeting unique pathways important in CSU are in development. This review focuses on the rationale behind, and results of, novel therapies trialed in CSU.
Medical subject headings
- Biological Products
- Chronic Urticaria